{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:27:15Z","timestamp":1793330835095,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Gene expression profiling (GEP) of primary cutaneous melanoma aims to offer prognostic and predictive information to guide clinical care. Despite limited evidence of clinical utility, these tests are increasingly incorporated into clinical care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A panel of melanoma experts from the Society of Surgical Oncology convened to develop recommendations regarding the use of GEP to guide management of patients with melanoma. The use of currently available GEP tests were evaluated in three clinical scenarios: (1) the utility in patient selection for sentinel lymph node biopsy; (2) the utility to guide surveillance; and (3) the utility to inform adjuvant therapy. As a basis for these recommendations, the panel performed a systematic review of the literature, including articles published from January 2012 until August 2023.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>After review of 137 articles,\u00a050\u00a0met the inclusion criteria. These articles included evidence related to three available GEP tests: 31-GEP, CP-GEP, and 11-GEP. The consensus recommendations were finalized using a modified Delphi process. The panel found that current evidence often fails to account for known clinicopathologic risk factors and lacks high-level data. The panel recognizes that the\u00a0study of GEP tests is still evolving. The integration of GEP into routine clinical practice for predicting sentinel lymph node status and patient prognosis in melanoma is therefore not currently recommended.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>At present, GEP should be considered primarily an investigational tool, ideally used in the context of clinical trials or specialized research settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-024-16379-2","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T13:03:02Z","timestamp":1730206982000},"page":"1429-1442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Society of Surgical Oncology Consensus Statement: Assessing the Evidence for and Utility of Gene Expression Profiling of Primary Cutaneous Melanoma"],"prefix":"10.1245","volume":"32","author":[{"given":"Edmund K.","family":"Bartlett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawnya","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Delman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina J.","family":"Hieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Society of Surgical Oncology Gene Expression Profiling Consensus Statement Work Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"1","key":"16379_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"16379_CR2","doi-asserted-by":"publisher","first-page":"MMT132","DOI":"10.2217\/mmt-2019-001632","volume":"6","author":"D Grossman","year":"2019","unstructured":"Grossman D, Kim CC, Hartman RI, et al. Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma Manag. 2019;6(4):MMT132. https:\/\/doi.org\/10.2217\/mmt-2019-001632.","journal-title":"Melanoma Manag"},{"key":"16379_CR3","unstructured":"NCCN Melanoma Guidelines Version 3.2023. NCCN, 2023. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1492. Cited 18 Nov 2023."},{"issue":"1","key":"16379_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","volume":"80","author":"SM Swetter","year":"2019","unstructured":"Swetter SM, Tsao H, Bichakjian C, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"16379_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamadermatol.2023.0127","volume":"159","author":"M Kashani-Sabet","year":"2023","unstructured":"Kashani-Sabet M, Leachman SA, Stein JA, et al. Early detection and prognostic assessment of cutaneous melanoma consensus on optimal practice and the role of gene expression profile testing. JAMA Dermatol. 2023;159(5):545\u201353.","journal-title":"JAMA Dermatol"},{"key":"16379_CR6","unstructured":"Centers for Medicare & Medicaid Services. Advanced diagnostic laboratory tests under the Medicare CLFS. https:\/\/www.cms.gov\/files\/document\/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf."},{"key":"16379_CR7","unstructured":"Medicare Coverage Database (MCD) MolDX: melanoma risk stratification molecular testing. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdId=37750&ver=24. Accessed 27 Aug 2022."},{"key":"16379_CR8","unstructured":"Genomeweb. Castle Bio receives expanded Medicare coverage for melanoma test. https:\/\/www.genomeweb.com\/reimbursement-news\/castle-bio-receives-expanded-medicare-coverage-melanoma-test. Accessed 28 Aug 2022."},{"key":"16379_CR9","unstructured":"SkylineDx announces Medicare coverage for its predictive melanoma assay Merlin Test. https:\/\/www.skylinedx.com\/news\/skylinedx-announces-medicare-coverage-for-its-predictive-melanoma-assay-merlin-test. Accessed 28 Aug 2022."},{"key":"16379_CR10","unstructured":"Centers for Medicare and Medicaid Services. Local coverage determination (LCD) L39365; genetic testing for oncology. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdId=39365&ver=80. Accessed 19 Jul 2023."},{"issue":"2","key":"16379_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.25251\/skin.5.2.4","volume":"5","author":"J Marson","year":"2021","unstructured":"Marson J, Litchman G, Svoboda R, Glazer A, Farberg A, Winkelmann R, Rigel D. Assessment of the 31-gene expression profile test by dermatologists: a cross-sectional survey from national dermatology conferences. SKIN J Cutan Med. 2021;5(2):101\u20137. https:\/\/doi.org\/10.25251\/skin.5.2.4.","journal-title":"SKIN J Cutan Med"},{"key":"16379_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41379-019-0402-x","volume":"33","author":"RA Scolyer","year":"2020","unstructured":"Scolyer RA, Rawson RV, Gershenwald JE, et al. Melanoma pathology reporting and staging. Mod Pathol. 2020;33:15\u201324.","journal-title":"Mod Pathol"},{"key":"16379_CR13","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1245\/s10434-019-07690-4","volume":"26","author":"ME Egger","year":"2019","unstructured":"Egger ME, Stevenson M, Bhutiani N, et al. Age and lymphovascular invasion accurately predict sentinel lymph node metastasis in T2 melanoma patients. Ann Surg Oncol. 2019;26:3955\u201361. https:\/\/doi.org\/10.1245\/s10434-019-07690-4.","journal-title":"Ann Surg Oncol"},{"key":"16379_CR14","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1177\/000313481107700816","volume":"77","author":"ME Egger","year":"2011","unstructured":"Egger ME, Gilbert JE, Burton AL, et al. Lymphovascular invasion as a prognostic factor in melanoma. Am Surg. 2011;77:992\u20137.","journal-title":"Am Surg"},{"key":"16379_CR15","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/modpathol.2017.76","volume":"30","author":"AHR Varey","year":"2017","unstructured":"Varey AHR, Goumas C, Hong AM, et al. Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. Mod Pathol. 2017;30:1538\u201350.","journal-title":"Mod Pathol"},{"key":"16379_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-62703-727-3_15","volume":"1102","author":"X Xu","year":"2014","unstructured":"Xu X, Gimotty PA, Guerry D, et al. Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma. Methods Mol Biol. 2014;1102:275\u201386.","journal-title":"Methods Mol Biol"},{"key":"16379_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1245\/s10434-018-7006-4","volume":"26","author":"GC Karakousis","year":"2019","unstructured":"Karakousis GC, Gimotty PA, Leong SP, et al. Microsatellitosis in patients with melanoma. Ann Surg Oncol. 2019;26:33\u201341. https:\/\/doi.org\/10.1245\/s10434-018-7006-4.","journal-title":"Ann Surg Oncol"},{"key":"16379_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2022.10.027","volume":"88","author":"C Riquelme-McLoughlin","year":"2023","unstructured":"Riquelme-McLoughlin C, Sandoval-Clavijo A, Blanco de Tord M, et al. Prognostic role of microsatellites in melanoma and implications in the American Joint Committee on Cancer classification systems: a cohort study. J Am Acad Dermatol. 2023;88:338\u201347.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"16379_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","journal-title":"CA Cancer J Clin"},{"key":"16379_CR20","unstructured":"NICE. Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | Guidance, 2022. https:\/\/www.nice.org.uk\/guidance\/ta837. Cited 19 Nov 2023."},{"key":"16379_CR21","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomized, double-blind, phase 3 trial. Lancet. 2022;399:1718\u201329.","journal-title":"Lancet"},{"key":"16379_CR22","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023;29:2835\u201343. https:\/\/doi.org\/10.1038\/s41591-023-02583-2.","journal-title":"Nat Med"},{"key":"16379_CR23","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMoa060992","volume":"355","author":"DL Morton","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307\u201317.","journal-title":"N Engl J Med"},{"key":"16379_CR24","unstructured":"Moncreiff MD, Lo SN, Scolyer RA, et al. Clinical outcomes and risk stratification of early-stage melanoma micrometastases from an international multicenter study: implications for the management of American Joint Committee on Cancer IIIA disease. J Clin Oncol. 2022;JCO2102488."},{"issue":"3","key":"16379_CR25","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1245\/s10434-022-12804-6","volume":"30","author":"Z Hussain","year":"2023","unstructured":"Hussain Z, Heaton MJ, Snelling AP, et al. Risk stratification of sentinel node metastasis disease burden and phenotype in stage iii melanoma patients. Ann Surg Oncol. 2023;30(3):1808\u201319. https:\/\/doi.org\/10.1245\/s10434-022-12804-6.","journal-title":"Ann Surg Oncol"},{"key":"16379_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/po.19.00206","volume":"4","author":"D Bellomo","year":"2020","unstructured":"Bellomo D, Arias-Mejias SM, Ramana C, et al. Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precis Oncol. 2020;4:319\u201334. https:\/\/doi.org\/10.1200\/po.19.00206.","journal-title":"JCO Precis Oncol"},{"key":"16379_CR27","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/PO.21.00162","volume":"5","author":"ED Whitman","year":"2021","unstructured":"Whitman ED, Koshenkov VP, Gastman BR, et al. Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction. JCO Precis Oncol. 2021;5:1466\u201379.","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"16379_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2020.1731","volume":"56","author":"MA Marchetti","year":"2020","unstructured":"Marchetti MA, Coit DG, Dusza SW, et al. Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2020;56(9):953\u201362. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1731.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"16379_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1245\/s10434-017-6267-7","volume":"25","author":"SL Wong","year":"2018","unstructured":"Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. Ann Surg Oncol. 2018;25(2):356\u201377. https:\/\/doi.org\/10.1245\/s10434-017-6267-7.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"16379_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Y Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129\u201342. https:\/\/doi.org\/10.1093\/jnci\/djq455.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"16379_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1245\/ASO.2005.05.016","volume":"12","author":"SL Wong","year":"2005","unstructured":"Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12(4):282\u20138. https:\/\/doi.org\/10.1245\/ASO.2005.05.016.","journal-title":"Ann Surg Oncol"},{"issue":"24","key":"16379_CR32","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1200\/JCO.19.02362","volume":"38","author":"NL Serigne","year":"2020","unstructured":"Serigne NL, Jiawen M, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Australia Nomogram. J Clin Oncol. 2020;38(24):2719\u201327.","journal-title":"J Clin Oncol"},{"issue":"3","key":"16379_CR33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1001\/jamasurg.2023.6904","volume":"159","author":"RO Bagge","year":"2024","unstructured":"Bagge RO, Mikiver R, Marchetti MA, et al. Population-based validation of the MIA and MSKCC tools for predicting sentinel lymph node status. JAMA Surg. 2024;159(3):260\u20138.","journal-title":"JAMA Surg"},{"issue":"7","key":"16379_CR34","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/jso.25720","volume":"120","author":"C Friedman","year":"2019","unstructured":"Friedman C, Lyon M, Torphy RJ, et al. A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. J Surg Oncol. 2019;120(7):1276\u201383.","journal-title":"J Surg Oncol"},{"issue":"6","key":"16379_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1245\/ASO.2003.10.001","volume":"10","author":"WR Wrightson","year":"2003","unstructured":"Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10(6):676\u201380. https:\/\/doi.org\/10.1245\/ASO.2003.10.001.","journal-title":"Ann Surg Oncol"},{"key":"16379_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-5945-12-21","volume":"12","author":"C Biver-Dalle","year":"2012","unstructured":"Biver-Dalle C, Puzenat E, Puyraveau M, et al. Sentinel lymph node biopsy in melanoma: our 8-year clinical experience in a single French institute (2002\u20132009). BMC Dematol. 2012;12:21.","journal-title":"BMC Dematol"},{"issue":"4","key":"16379_CR37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ajd.12662","volume":"58","author":"DE Gyorki","year":"2017","unstructured":"Gyorki DE, Barbour A, Hanikeri M, Mar V, Sandhu S, Thompson JF. When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the \u2018Australian guidelines for the management of cutaneous melanoma.\u2019 Australas J Dematol. 2017;58(4):274\u20137.","journal-title":"Australas J Dematol"},{"issue":"12","key":"16379_CR38","doi-asserted-by":"publisher","first-page":"107249","DOI":"10.1016\/j.ejso.2023.107249","volume":"49","author":"RC Stassen","year":"2023","unstructured":"Stassen RC, Mulder EAP, et al. Clinical evaluation of clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy. A multicenter prospective Dutch study. Eur J Surg Oncol. 2023;49(12):107249.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"16379_CR39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ejso.2021.11.010","volume":"48","author":"I Johansson","year":"2022","unstructured":"Johansson I, Tempel D, Dwarkasing JT, et al. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. Eur J Surg Oncol. 2022;48(2):320\u20135.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"16379_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/ijd.15594","volume":"60","author":"A Yousaf","year":"2021","unstructured":"Yousaf A, Tjien-Fooh FJ, Rentroia-Pacheco B, et al. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study. Int J Dermatol. 2021;60(7):851\u20136.","journal-title":"Int J Dermatol"},{"issue":"5","key":"16379_CR41","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/bjd.19499","volume":"184","author":"E Mulder","year":"2021","unstructured":"Mulder E, Dwarkasing JT, Tempel D, et al. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma. Br J Dermatol. 2021;184(5):944\u201351.","journal-title":"Br J Dermatol"},{"key":"16379_CR42","unstructured":"SkylineDx. Melanoma research lymph node prediction implementation national_001 (MERLIN_001). https:\/\/clinicaltrials.gov\/study\/NCT04759781. Accessed May 2024."},{"issue":"11","key":"16379_CR43","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/fon-2018-0912","volume":"15","author":"JT Vetto","year":"2019","unstructured":"Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1\u2013T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207\u201317.","journal-title":"Future Oncol"},{"key":"16379_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaad.2018.07.028","volume":"80","author":"BR Gastman","year":"2019","unstructured":"Gastman BR, Gerami P, Kurley SJ, et al. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80:149-157.e4.","journal-title":"J Am Acad Dermatol"},{"key":"16379_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","volume":"18","author":"JS Zager","year":"2018","unstructured":"Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18:130.","journal-title":"BMC Cancer"},{"issue":"3","key":"16379_CR46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2020.03.053","volume":"83","author":"BN Greenhaw","year":"2020","unstructured":"Greenhaw BN, Covington KR, Kurley SJ, et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. J Am Acad Dermatol. 2020;83(3):745\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"16379_CR47","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1080\/03007995.2016.1192997","volume":"32","author":"AC Berger","year":"2016","unstructured":"Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016;32(9):1599\u2013609.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"16379_CR48","first-page":"428","volume":"16","author":"AS Farberg","year":"2017","unstructured":"Farberg AS, Glazer AM, White R, Rigel DS. Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists\u2019 clinical management decisions. J Drugs Dermatol. 2017;16(5):428\u201331.","journal-title":"J Drugs Dermatol"},{"key":"16379_CR49","first-page":"28","volume":"28","author":"S Dhillon","year":"2023","unstructured":"Dhillon S, Duarte-Bateman D, Fowler G, et al. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. Arch Dematol Res. 2023;28:28.","journal-title":"Arch Dematol Res"},{"key":"16379_CR50","doi-asserted-by":"publisher","first-page":"e2300044","DOI":"10.1200\/PO.23.00044","volume":"7","author":"CN Bailey","year":"2023","unstructured":"Bailey CN, Martin BJ, Petkov VI, et al. 31-gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: a SEER collaboration. JCO Precis Oncol. 2023;7:e2300044.","journal-title":"JCO Precis Oncol"},{"key":"16379_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2022.12.021","volume":"182","author":"T Amaral","year":"2023","unstructured":"Amaral T, Sinnberg T, Chatziioannou E, et al. Identification of stage I\/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP_GEP). Eur J Cancer. 2023;182:155\u201362.","journal-title":"Eur J Cancer"},{"issue":"12","key":"16379_CR52","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.3390\/cancers14122854","volume":"14","author":"EAP Mulder","year":"2022","unstructured":"Mulder EAP, Johnsson I, Gr\u00fcnhagen DJ, et al. Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I-II melanoma patients at risk of disease relapse. Cancers. 2022;14(12):2854.","journal-title":"Cancers"},{"key":"16379_CR53","doi-asserted-by":"crossref","unstructured":"Amaral T, Forchlammer S, Chatziioannou E, et al. Clinical validation of a prognostic 7-marker IHC assay (7-IHC) in 382 patients (pts) with stage IB\/IIA cutaneous melanoma (CM; MELARISK-001). J Clin Oncol. 2024;42(Suppl 16):abstr 9572.","DOI":"10.1200\/JCO.2024.42.16_suppl.9572"},{"key":"16379_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","volume":"125","author":"TMS Amaral","year":"2020","unstructured":"Amaral TMS, Hoffmann MC, Sinnberg T, et al. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. Eur J Cancer. 2020;125:38\u201345.","journal-title":"Eur J Cancer"},{"key":"16379_CR55","unstructured":"ClinicalTrials.gov. Adjuvant nivolumab treatment in state II (IIA, IIB, IIC) high-risk melanoma (NivoMela). https:\/\/clinicaltrials.gov\/study\/NCT04309409?cond=NCT04309409&rank=1. Accessed May 2024."},{"issue":"9","key":"16379_CR56","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1001\/jamadermatol.2020.1729","volume":"156","author":"D Grossman","year":"2020","unstructured":"Grossman D, Okwundu N, Bartlett EK, et al. Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit. JAMA Dermatol. 2020;156(9):1004\u201311.","journal-title":"JAMA Dermatol"},{"key":"16379_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-4939-7493-1_10","volume":"1711","author":"C Gomez","year":"2018","unstructured":"Gomez C, Hartung N. Stochastic and deterministic models for the metastatic emission process: formalisms and crosslinks. Methods Mol Biol. 2018;1711:193\u2013224.","journal-title":"Methods Mol Biol"},{"key":"16379_CR58","doi-asserted-by":"publisher","first-page":"20130011","DOI":"10.1098\/rsif.2013.0011","volume":"10","author":"JG Scott","year":"2013","unstructured":"Scott JG, Basanta D, Anderson ARA, et al. A mathematical model of tumour self-seeding reveals secondary metastatic deposits as drivers of primary tumour growth. JR Soc Interface. 2013;10:20130011.","journal-title":"JR Soc Interface"},{"issue":"1","key":"16379_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaad.2018.03.054","volume":"80","author":"ME Klapperich","year":"2019","unstructured":"Klapperich ME, Bowen GM, Grossman D. Current controversies in early-stage melanoma: questions on management and surveillance. J Am Acad Dermatol. 2019;80(1):15\u201325. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.054.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"16379_CR60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jamcollsurg.2016.12.038","volume":"224","author":"AC Berger","year":"2017","unstructured":"Berger AC, Ollila DW, Christopher A, et al. Patient symptoms are the most frequent indictors of recurrence in patients with American Joint Committee on Cancer Stage II melanoma. J Am Coll Surg. 2017;224(4):652\u20139.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"16379_CR61","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jaad.2019.08.022","volume":"82","author":"A Varedi","year":"2020","unstructured":"Varedi A, Gardner LJ, Kim CC, et al. Use of new molecular tests for melanoma by pigmented-lesion experts. J Am Acad Dermatol. 2020;82(1):245\u20137.","journal-title":"J Am Acad Dermatol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16379-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16379-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16379-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T13:38:47Z","timestamp":1739194727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16379-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["16379"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16379-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Giorgos Karakousis has received research funding from Merck; was the Principal Investigator (PI) of an investigator-initiated trial on neoadjuvant PD-1 therapy for clinical stage II B\/C melanoma from 2019 to the present (research monies to support the trial and studies are paid to the institution); and is a member of the Advisory Boards for Merck and Bristol Myers Squibb (no direct relationships to the project). Tina J. Hieken has received research funding from Genentech and SkylineDx (current research funding is paid to the institution). Genevieve Boland is a consultant and advisor, and has received research funding. She has been a speaker for Novartis and Takeda Oncology (2019); a consultant for NW Biotherapeutics (2020), Merck (2021), InterVenn Biosciences (2021), and Ankyra Therapeutics (2021); a member of the Advisory Boards of Iovance (2021, 2023) and Merck (2021, 2022, 2023); a member of the Scientific Advisory Board and Steering Committee for Nektar Therapeutics (2020); a member of the Surgical Advisory Board for Novartis (2020); a member of the Scientific Advisory Board for Ankyra Therapeutics (2021, 2022, 2023) and Moderna (June 2024); had sponsored research agreements for Olink Proteomics, Palleon Pharmaceuticals, and InterVenn Biosciences (2021); and held stock in Ankyra Therapeutics (2021). Marc Moncrieff is an advisor and has received honoraria, travel expenses, and research funding. He was the recipient of a grant from the UK National Institute for Health and Care Research (NIHR, grant 19\/102: 130886); received an honorarium and travel expenses from Novartis, Canada, in December 2019; and received an honorarium from Amgen to attend an advisory panel session in October 2019. Edmund K. Bartlett received honoraria from Excite International in 2021; received research funding and institutional research support from Skyline Dx (Rotterdam, The Netherlands, and San Diego, CA, USA) pertaining to the Merlin Assay that is ongoing; and institutional research support from Qbiotics Group. Tawnya Bowles received research funding from Genentech (2019 to the present), and was PI for a melanoma clinical research study, PI for a clinical research study conducted by Amgen (2018 to the present), PI for a clinical research study conducted by Replimune (2019 to the present), and PI for a clinical research study conducted by Natera (2020 to the present); however, she does not receive any direct funds from these sources. Cristina O\u2019Donoghue, Keith A. Delman, Sandra Wong, and Richard L. White Jr have no conflicts of interest to declare that may be relevant to the contents of this article. Authors and reviewers have disclosed potential conflicts of interest consistent with SSO policy. Disclosures are also listed in the Appendix.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Comments on this document may be sent to the SSO for consideration in future iterations of the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Comments"}}]}}